Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NSAIDs Vs. COX-2s: Study Prompts Labeling Review By FDA On Merck’s Vioxx

This article was originally published in The Tan Sheet

Executive Summary

OTC NSAID manufacturers may have been handed a significant marketing opportunity against COX-2s in the form of results from a retrospective study indicating the Rx pain relievers carry a higher risk of a serious cardiac event compared to their nonprescription counterparts

You may also be interested in...



Pfizer’s COX-2 Scripts Take More Hits From Kaiser

A decision by Kaiser Permanente physicians in California to stop prescribing Bextra demonstrates the challenges Pfizer must overcome as it seeks to reassure the public about the cardiovascular safety of COX-2 inhibitors

Pfizer’s COX-2 Scripts Take More Hits From Kaiser

A decision by Kaiser Permanente physicians in California to stop prescribing Bextra demonstrates the challenges Pfizer must overcome as it seeks to reassure the public about the cardiovascular safety of COX-2 inhibitors

Pfizer’s COX-2 Scripts Take More Hits From Kaiser

A decision by Kaiser Permanente physicians in California to stop prescribing Bextra demonstrates the challenges Pfizer must overcome as it seeks to reassure the public about the cardiovascular safety of COX-2 inhibitors

Related Content

Topics

UsernamePublicRestriction

Register

PS097228

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel